Crossmark

Non-invasive Vagal Nerve Stimulation Decreases the Need for Rescue Medication for Nausea Exacerbation in Patients with Chronic Nausea and Vomiting

Crossref DOI link: https://doi.org/10.1007/s10620-025-09457-2

Published Online: 2025-10-16

Published Print: 2026-03

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Barahona, Guillermo https://orcid.org/0000-0002-1645-2912
de Barahona, Luisa Villatoro https://orcid.org/0009-0006-4869-6459
Sidhu, Samarth S. https://orcid.org/0009-0008-4626-0015
Burns, Robert https://orcid.org/0009-0001-0915-8416
McKnight, Megan

Hui, Ken Y.

Bulat, Robert

Treisman, Glenn J. https://orcid.org/0000-0003-4578-6150
Liebler, Eric https://orcid.org/0000-0002-8083-9660
McClure, Candace K. https://orcid.org/0000-0002-5316-4792
Pasricha, Pankaj J.
License Information

Text and Data Mining valid from 2025-10-16

Version of Record valid from 2025-10-16
More Information

Article History

Received: 11 December 2024

Accepted: 29 September 2025

First Online: 16 October 2025

Declarations

:

: Eric Liebler is a consultant for and owns stock in electroCore, Inc.

: This study, titled “Non-invasive vagal nerve stimulation (nVNS) for symptomatic exacerbation of nausea in patients with gastroparesis and related disorders,” was conducted in accordance with the ethical guidelines and regulations set forth by the Johns Hopkins University Institutional Review Board (IRB). This study was performed in line with the principles of the declaration of Helsinki. The research was approved under Protocol ID IRB00265410 on March 10, 2021. The study is registered with ClinicalTrials.gov under the identifier NCT04857281. All participants provided informed consent prior to their involvement in the study.

: Informed consent was obtained from all individual participants included in this study.

Document is current

Any future updates will be listed below